Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pevonedistat (Primary) ; Irinotecan; Temozolomide
  • Indications CNS cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 22 Oct 2024 Status changed from active, no longer recruiting to completed.
  • 13 Oct 2023 Protocol has been amended to change in time frame for Toxicities Associated With Pevonedistat in Combination With Irinotecan and Temozolomide Up to 3 years 8 months
  • 13 Oct 2023 Planned End Date changed from 5 Oct 2022 to 22 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top